Longeveron (LGVN) News Today $0.68 -0.59 (-46.62%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.68 0.00 (-0.28%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LGVN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Longeveron Announces Up To $17.5 Million Public OfferingAugust 8 at 1:28 PM | globenewswire.comLongeveron Inc. to Announce Q2 2025 Financial Results and Business Update on August 13, 2025August 5, 2025 | quiverquant.comQLongeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025August 5, 2025 | globenewswire.comLongeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular DiseaseJuly 21, 2025 | globenewswire.comLongeveron receives FDA approval for pediatric heart therapy INDJuly 10, 2025 | uk.investing.comLongeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric ... - Seeking AlphaJuly 10, 2025 | seekingalpha.comLongeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - NasdaqJuly 10, 2025 | nasdaq.comLongeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)July 9, 2025 | finanznachrichten.deLongeveron stock soars after FDA approves IND for heart failure treatmentJuly 9, 2025 | in.investing.comLGVN Announces Groundbreaking Treatment Approved for TrialJuly 9, 2025 | msn.comLongeveron Shares Jump as FDA Clears Phase 2 Trial for Pediatric Heart TherapyJuly 9, 2025 | msn.comLongeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)July 8, 2025 | globenewswire.comLongeveron Inc. Appoints Than Powell as Chief Business Officer to Lead Partnering and International Strategy - NasdaqJune 28, 2025 | nasdaq.comLongeveron Inc. Appoints Than Powell as Chief Business Officer to Lead Partnering and International StrategyJune 26, 2025 | quiverquant.comQLongeveron® Appoints Than Powell as Chief Business OfficerJune 26, 2025 | globenewswire.comLGVN Announces Pivotal Test UpdateJune 24, 2025 | msn.comLongeveron Inc. Completes Enrollment for Phase 2b ELPIS II Trial Evaluating Laromestrocel for Hypoplastic Left Heart Syndrome, With Results Expected in Q3 2026June 24, 2025 | quiverquant.comQLongeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)June 24, 2025 | globenewswire.comLongeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 11, 2025 | nasdaq.comLongeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 9, 2025 | globenewswire.comLongeveron Inc. (NASDAQ:LGVN) Director Sells $13,000.00 in StockJune 3, 2025 | insidertrades.comHere's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash WiselyMay 29, 2025 | finance.yahoo.comLongeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International ConventionMay 22, 2025 | nasdaq.comLongeveron Inc.May 21, 2025 | marketwatch.comLongeveron® to Attend BIO International Convention 2025May 20, 2025 | globenewswire.comLongeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award RecipientMay 12, 2025 | globenewswire.comLongeveron Inc. (LGVN) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comLGVN Entering Crucial Period in Great ShapeMay 9, 2025 | msn.comRoth MKM Remains a Buy on Longeveron (LGVN)May 9, 2025 | theglobeandmail.comLongeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 9, 2025 | finance.yahoo.comLongeveron® Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | finance.yahoo.comLongeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025May 2, 2025 | globenewswire.comLongeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025April 23, 2025 | finance.yahoo.comLongeveron Inc. CEO Shares 2024 Progress and Strategic Goals for 2025 in Shareholder LetterApril 22, 2025 | quiverquant.comQLongeveron Stock Short Interest Report | NASDAQ:LGVN | BenzingaApril 18, 2025 | benzinga.comLGVN Announces Positive Alzheimer’s NewsMarch 20, 2025 | msn.comLongeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s DiseaseMarch 20, 2025 | finance.yahoo.comLongeveron (LGVN) Receives a Buy from Roth MKMMarch 20, 2025 | markets.businessinsider.comRoth MKM Keeps Their Buy Rating on Longeveron (LGVN)March 11, 2025 | markets.businessinsider.comLongeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's DiseaseMarch 11, 2025 | finanznachrichten.deLongeveron announces publication of results of Phase 2a trial of Lomecel-BMarch 11, 2025 | markets.businessinsider.comLongeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's DiseaseMarch 11, 2025 | globenewswire.comLongeveron® to Present at the 37th Annual Roth ConferenceMarch 5, 2025 | globenewswire.comRoth MKM Sticks to Its Buy Rating for Longeveron (LGVN)March 4, 2025 | markets.businessinsider.comLongeveron Inc. Earnings Call: Growth and ChallengesMarch 3, 2025 | tipranks.comLGVN Well Positioned for Critical 2025March 3, 2025 | msn.comLongeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | insidermonkey.comEarnings call transcript: Longeveron Q4 2024 sees revenue surge, stock gainsMarch 2, 2025 | investing.comAnalysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before LongMarch 2, 2025 | finance.yahoo.comLongeveron reports Q4 revenue $700,000, consensus $637,500March 1, 2025 | markets.businessinsider.com Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address LGVN Media Mentions By Week LGVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGVN News Sentiment▼0.200.49▲Average Medical News Sentiment LGVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGVN Articles This Week▼51▲LGVN Articles Average Week Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PLRX News ANIX News ONCY News ZNTL News SRZN News VIRI News SCLX News TCRX News ADAG News QNCX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGVN) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
